Treatment Options for Neurotrophic Keratitis

Drs. Fasika Woreta and Brenton Finklea review the disease stages of neurotrophic keratitis and treatment based on staging. Therapy options include traditional lubricants and therapeutic contact lenses, cryopreserved amniotic membrane, newer agents such as cenegermin (Oxervate), and surgical interventions such as corneal neurotization and tarsorrhaphy.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

CME Information

Release: April 7, 2022; expires April 7, 2025.

Financial Disclosures:
Planner/Faculty: Dr. Sridhar receives consulting fees from Allergan and Alcon.
Faculty: Dr. Finklea receives consulting or lecture fees from CorneaGen. Dr. Woreta reports no relevant financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.

Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of neurotrophic keratitis and how these standards impact patient care decisions.

Audience: This activity is intended for comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.